An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study

Creative Commons License

Eldem B., Lai T. Y. Y., Ngah N. F., Vote B., Yu H. G., Fabre A., ...More

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol.256, no.5, pp.963-973, 2018 (SCI-Expanded) identifier identifier identifier


To describe intravitreal ranibizumab treatment frequency, clinical monitoring, and visual outcomes (including mean central retinal thickness [CRT] and visual acuity [VA] changes from baseline) in neovascular age-related macular degeneration (nAMD) in real-world settings across three ranibizumab reimbursement scenarios in the Middle East, North Africa, and the Asia-Pacific region.